专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

US20110319415A1 Susceptibility to HSP90-Inhibitors 审中-公开
标题翻译：对HSP90抑制剂的敏感性
公开(公告)号：US20110319415A1
公开(公告)日：2011-12-29
申请号：US13059557
申请日：2009-08-17
申请人： Roman Thomas , Kathrin Maring , Thomas Zander , Peter Frommolt , Kwok-kin Wong
发明人： Roman Thomas , Kathrin Maring , Thomas Zander , Peter Frommolt , Kwok-kin Wong
IPC分类号： A61K31/395 , C12Q1/68 , G01N33/567 , A61K31/5377 , A61P35/00 , A61P35/02 , C40B30/04 , C12Q1/02
CPC分类号： G01N33/574 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N2800/52
摘要： The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to an HSP90 inhibitor and uses of an oligo- or polynucleotide capable of detecting (an) activating mutation(s) in the KRAS gene are provided. The present invention also relates to a method of monitoring the efficacy of a treatment of a cancer characterized by the presence of at least one activating mutation in the KRAS gene, and. optionally, in the EGFR gene and/or the BRAF gene. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular in a cancer that is characterized by the presence of at least one activating mutation in the KRAS gene. and. optionally, in the EGFR gene and/or the BRAF gene. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one activating mutation in the KRAS gene, and, optionally, in the EGFR gene and/or the BRAF gene for screening and/or validation of a medicament for the treatment of said cancer is described and a kit useful for carrying out the methods described herein is provided.
摘要翻译：本发明涉及一种选择（a）对HSP90抑制剂具有敏感性的细胞，（a）组织或（a）细胞培养物的方法。本文还描述了确定哺乳动物肿瘤细胞或癌细胞对用HSP90抑制剂进行治疗的反应性的方法。特别地，本发明提供了用于鉴定对HSP90抑制剂敏感的或对其敏感的患者的体外方法，以及能够检测（或）激活KRAS基因突变的寡核苷酸或多核苷酸的用途被提供。本发明还涉及一种监测癌症治疗功效的方法，其特征在于在KRAS基因中存在至少一种激活突变。任选地，在EGFR基因和/或BRAF基因中。此外，描述了预测癌症治疗功效的方法，特别是在KRAS基因中存在至少一种激活突变的癌症中。和。任选地，在EGFR基因和/或BRAF基因中。另外，在KRAS基因和/或任选地在EGFR基因和/或BRAF基因中具有至少一个激活突变的（转基因）非人动物或（转基因）细胞也用于筛选和/或验证描述了用于治疗所述癌症的药物，并提供了可用于实施本文所述方法的试剂盒。

IPRDB

热门服务

关于我们

友情链接

联系方式